Company intelligence / Profile preview
Bora Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Bora Pharmaceuticals is an international pharmaceutical services company operating at commercial scale. It provides contract development and manufacturing for small molecule drugs, biologics, sterile injectables, and complex dosage forms. The company has expanded into rare disease markets and specialty generics through acquisitions such as Upsher-Smith Laboratories and Pyros. Its commercial business includes successful launches like Dexlansoprazole DR in the US and VIGAFYDE™ for pediatric spasms. The company reported record revenues nearing NT$20 billion (~US$600M) in 2024 with continued growth into 2025.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurologyCardiovascular
- Modalities
- Small moleculesBiologicsSterile injectables
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Bora Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bora Pharmaceuticals.